Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16 2020 - 3:30PM
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global
biopharmaceutical company pioneering targeted C3 therapies, today
announced that the company approved the grant of an equity award to
a new employee with a grant date of January 13, 2020, as an equity
inducement award outside of the company's 2017 Stock Incentive Plan
and material to the employee’s acceptance of employment with the
company. The equity award was approved on December 13, 2019, in
accordance with Nasdaq Listing Rule 5635(c)(4).
The employee received an option to purchase 3,000 shares of
Apellis common stock. The option has an exercise price of $40.34
per share, which is equal to the closing price of Apellis common
stock on January 13, 2020, the grant date of the option. One-fourth
of the shares underlying the employee option will vest on the one
year anniversary of the employee’s date of employment and
thereafter 1/48th of the shares underlying the employee option will
vest monthly, such that the shares underlying the option granted to
the employee will be fully vested on the fourth anniversary of the
employee’s date of hire, subject to the employee’s continued
employment with Apellis on such vesting dates.
About Apellis Apellis Pharmaceuticals, Inc. is
a global biopharmaceutical company that is committed to leveraging
courageous science, creativity, and compassion to deliver
life-changing therapies. By pioneering targeted C3 therapies, we
aim to develop best-in-class and first-in-class therapies for a
broad range of debilitating diseases that are driven by
uncontrolled or excessive activation of the complement cascade,
including those within hematology, ophthalmology, and nephrology.
For more information, please visit http://apellis.com.
Apellis Forward-Looking Statement Statements in
this press release about future expectations, plans and prospects,
as well as any other statements regarding matters that are not
historical facts, may constitute “forward-looking statements”
within the meaning of The Private Securities Litigation Reform Act
of 1995. These statements include, but are not limited to,
statements relating to the implications of preliminary clinical
data. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “will,” “would” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including: whether preliminary or
interim results from a clinical trial will be predictive of the
final results of the trial; whether results obtained in preclinical
studies and clinical trials such as the results reported in this
release will be indicative of results that will be generated in
future clinical trials; whether pegcetacoplan will successfully
advance through the clinical trial process on a timely basis, or at
all; whether the results of such clinical trials will warrant
regulatory submissions and whether pegcetacoplan will receive
approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies for GA, PNH, C3G or any
other indication; whether, if Apellis’ products receive approval,
they will be successfully distributed and marketed; and other
factors discussed in the “Risk Factors” section of Apellis’
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on November 5, 2019, and the risks described in
other filings that Apellis may make with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Apellis
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Investor Contact: Sam Martin / Maghan
Meyers Argot Partners
sam@argotpartners.com / maghan@argotpartners.com
212.600.1902
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Apr 2024 to May 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From May 2023 to May 2024